Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation
Main Article Content
Abstract
The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard
of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration
of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has
shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish
Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for
hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t)
ide analogs after liver transplantation.
of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration
of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has
shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish
Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for
hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t)
ide analogs after liver transplantation.